Cargando…
Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis
Pyrazinamide (PZA) is a key antibiotic for the treatment of drug susceptible tuberculosis. PZA-resistance is mainly mediated by mutations in the pncA gene; however the current gold standard is a phenotypic drug susceptibility test requiring a well-adjusted pH-value for reliable results. Our melting...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Biomedical
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531379/ https://www.ncbi.nlm.nih.gov/pubmed/30733004 http://dx.doi.org/10.1016/j.diagmicrobio.2018.12.011 |
_version_ | 1783420815602089984 |
---|---|
author | Havlicek, Juliane Dachsel, Beatrice Slickers, Peter Andres, Sönke Beckert, Patrick Feuerriegel, Silke Niemann, Stefan Merker, Matthias Labugger, Ines |
author_facet | Havlicek, Juliane Dachsel, Beatrice Slickers, Peter Andres, Sönke Beckert, Patrick Feuerriegel, Silke Niemann, Stefan Merker, Matthias Labugger, Ines |
author_sort | Havlicek, Juliane |
collection | PubMed |
description | Pyrazinamide (PZA) is a key antibiotic for the treatment of drug susceptible tuberculosis. PZA-resistance is mainly mediated by mutations in the pncA gene; however the current gold standard is a phenotypic drug susceptibility test requiring a well-adjusted pH-value for reliable results. Our melting curve assay detects a non-wild type genotype in selected pncA regions in at least 3750 gene copies/mL within 2.5 hours. The prototype assay was further evaluated by analyzing 271 Mycobacterium tuberculosis complex isolates from Swaziland originating from a previously published drug resistance survey and including 118 isolates with pncA mutations. Sensitivity was 83% (95% CI 75–89%) and specificity was 100% (95% CI 98–100%). Under consideration of further improvements with regard to the target range our melting curve assay has the potential as a rapid rule-in test for PZA susceptibility (wild type pncA), however false resistant results (mutant pncA, but PZA susceptible) cannot be ruled out completely. |
format | Online Article Text |
id | pubmed-6531379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier Biomedical |
record_format | MEDLINE/PubMed |
spelling | pubmed-65313792019-06-01 Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis Havlicek, Juliane Dachsel, Beatrice Slickers, Peter Andres, Sönke Beckert, Patrick Feuerriegel, Silke Niemann, Stefan Merker, Matthias Labugger, Ines Diagn Microbiol Infect Dis Article Pyrazinamide (PZA) is a key antibiotic for the treatment of drug susceptible tuberculosis. PZA-resistance is mainly mediated by mutations in the pncA gene; however the current gold standard is a phenotypic drug susceptibility test requiring a well-adjusted pH-value for reliable results. Our melting curve assay detects a non-wild type genotype in selected pncA regions in at least 3750 gene copies/mL within 2.5 hours. The prototype assay was further evaluated by analyzing 271 Mycobacterium tuberculosis complex isolates from Swaziland originating from a previously published drug resistance survey and including 118 isolates with pncA mutations. Sensitivity was 83% (95% CI 75–89%) and specificity was 100% (95% CI 98–100%). Under consideration of further improvements with regard to the target range our melting curve assay has the potential as a rapid rule-in test for PZA susceptibility (wild type pncA), however false resistant results (mutant pncA, but PZA susceptible) cannot be ruled out completely. Elsevier Biomedical 2019-06 /pmc/articles/PMC6531379/ /pubmed/30733004 http://dx.doi.org/10.1016/j.diagmicrobio.2018.12.011 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Havlicek, Juliane Dachsel, Beatrice Slickers, Peter Andres, Sönke Beckert, Patrick Feuerriegel, Silke Niemann, Stefan Merker, Matthias Labugger, Ines Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis |
title | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis |
title_full | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis |
title_fullStr | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis |
title_full_unstemmed | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis |
title_short | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis |
title_sort | rapid microarray-based assay for detection of pyrazinamide resistant mycobacterium tuberculosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531379/ https://www.ncbi.nlm.nih.gov/pubmed/30733004 http://dx.doi.org/10.1016/j.diagmicrobio.2018.12.011 |
work_keys_str_mv | AT havlicekjuliane rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT dachselbeatrice rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT slickerspeter rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT andressonke rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT beckertpatrick rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT feuerriegelsilke rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT niemannstefan rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT merkermatthias rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis AT labuggerines rapidmicroarraybasedassayfordetectionofpyrazinamideresistantmycobacteriumtuberculosis |